Azacitidine (5-Azacytidine)

Name: Azacitidine (5-Azacytidine)
Brand: Selleck Chemicals
SKU: S1782
Rating: 5 (46 reviews)

For research use only.

Catalog No.S1782 Synonyms: 5-AzaC,Ladakamycin, AZA,5-Aza

46 publications

Azacitidine (5-Azacytidine) Chemical Structure

CAS No. 320-67-2

Azacitidine (5-Azacytidine, 5-AzaC, Ladakamycin, AZA, 5-Aza) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases. Azacitidine induces mitochondrial apoptosis and autophagy.

Selleck's Azacitidine (5-Azacytidine) has been cited by 46 publications

Cancer Cell, 2019, 35(2):333-335

PubMed: 30753831 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):724-740.e4

PubMed: 30423294 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31382-X

PubMed: 29249359 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E259

PubMed: 33445642 ( click the link to review the publication )

Transgenic Res, 2021, 30(1):63-76

PubMed: 33394315 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Neoplasia, 2020, 22(3):142-153

PubMed: 32062068 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Technol Cancer Res Treat, 2020,

PubMed: 32715976 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4393-4405

PubMed: 32926125 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Clin Transl Oncol, 2020, 10.1007/s12094-020-02464-x

PubMed: 32737836 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

J Biochem Mol Toxicol, 2020, e22621

PubMed: 32894642 ( click the link to review the publication )

Stem Cell Reports, 2020, 15(2):408-423

PubMed: 32735821 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI128571

PubMed: 31437130 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )
Cell Commun Signal, 2019, 17(1):4

PubMed: 30642362 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Environ Toxicol, 2019, 10.1002/tox.22873

PubMed: 31724259 ( click the link to review the publication )

J Pharmacol Sci, 2019, 140(2):187-192

PubMed: 31345653 ( click the link to review the publication )

Med Sci Monit, 2019, 25:9426-9434

PubMed: 31822650 ( click the link to review the publication )

Commun Biol, 2019, 2:272

PubMed: 31372511 ( click the link to review the publication )

Blood, 2018, 131(14):1576-1586

PubMed: 29437595 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30412053 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 5;37(1):305

PubMed: 30518424 ( click the link to review the publication )

PLoS Pathog, 2018, 14(6):e1007061

PubMed: 29879225 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2091-2099

PubMed: 30045927 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(5)E1414

PubMed: 29747401 ( click the link to review the publication )

Int J Mol Sci, 2018, 20(1)

PubMed: 30577584 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(9):1243-1254

PubMed: 28522693 ( click the link to review the publication )

Leuk Res, 2017, 58:91-97

PubMed: 28505595 ( click the link to review the publication )

Leuk Res, 2017, 56:36-43

PubMed: 28171800 ( click the link to review the publication )

FEBS J, 2016, 283(20):3739-3754

PubMed: 27573079 ( click the link to review the publication )

Oncotarget, 2016, 8(60):100975-100988

PubMed: 29254139 ( click the link to review the publication )

Sci Transl Med, 2015, 7(290):290ra89

PubMed: 26041706 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methyltransferase ^[1]
(Cell-free assay)

In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. ^[1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. ^[2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Raji	MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDLNE4yNTVyIN88US=>	NILrbIkyOi15MjDo		M4DwZYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MlnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{OyOFYoRjJ4MUOzNlQ3RC:jPh?=
Jurkat	NHO1VoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33SWVAvOS13MDFOwG0>	MVmxNk04OiCq		NXTYfHRzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NXfJWVJYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|MzPDZpPkK2NVM{OjR4PD;hQi=>
CA46	M1fmT2Z2dmO2aX;uJGF{e2G7	NFfsfmwzOMLiwsXN	M4j3clQ5KGh?		M{f3Xolv[3KnYYPld:KhWFSSTEJCpI1TVkFiZYjwdoV{e2mxbh?=	MlzhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{OyOFYoRjJ4MUOzNlQ3RC:jPh?=
Raji	NVe3NYJxTnWwY4Tpc44hSXO\|YYm=	NFW1XWIyPcLiwsXN	MlrBOFghcA>?		MULpcoNz\WG\|ZYRCpHBVWExzwrDtVm5CKGW6cILld5Nqd25?	NVL6fmJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|MzPDZpPkK2NVM{OjR4PD;hQi=>
Jurkat	MoqwSpVv[3Srb36gRZN{[Xl?	NVPEV2VoOy53wrFCuW0>	M2TRR\|Q5KGh?		MmPCbY5kemWjc3XzxsBRXFCOMdMgcXJPSSCneIDy[ZN{cW:w	M1T5cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUOzNlQ3Lz5{NkGzN\|I1PjxxYU6=
MDA-MB-231	MWnGeY5kfGmxbjDBd5NigQ>?	M3njWlEwOi53L{Wg{txO	NXLNWI81PDhiaB?=		NXfwbYNt\GWlcnXhd4V{KHSqZTDQWHBPOTJiZYjwdoV{e2mxbjDheEB1cGViY3;uZ4VzdnS{YYTpc44hd2ZiNdMg{txOKDR6wrDo	NHKzRWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixO\|IzQSd-MkW4NVczOjl:L3G+
MDA-MB-231	NY\ZXJh2TnWwY4Tpc44hSXO\|YYm=	NXiz[Zc6OS9{LkWvOUDPxE1?	NXX0PGtNPDhiaB?=		NFLMN29qdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDFMYNi\GincnnuJI1TVkFiYYSgeIhmKGOxbnPldo51emG2aX;uJI9nKDJwNdMg{txO\m:{IES4xsBp	M3PMNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEG3NlI6Lz5{NUixO\|IzQTxxYU6=
MDA-MB-231	MWDGeY5kfGmxbjDBd5NigQ>?	M2TFfVEwOi53L{Wg{txO	MV[yOE81QCCq		NULrbpVNcW6mdXPld{Ahe2mpbnnmbYNidnRiUFHSVEBkdGWjdnHn[UBi\nSncjC0PEBp	MkDvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUeyNlkoRjJ3OEG3NlI6RC:jPh?=
MCF-7	MmjqSpVv[3Srb36gRZN{[Xl?	NFrifFUyNzJwNT:1JO69VQ>?	MXGyOE81QCCq		NGfVXVBqdmO{ZXHz[ZMhWEGUUDDjcIVifmGpZdMg	NWTL[HhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVczOjlpPkK1PFE4OjJ7PD;hQi=>
MDA-MB-231	M1HRVWZ2dmO2aX;uJGF{e2G7	NVj2WJBpOS9{LkWvOUDPxE1?	NULzbnJ3OjRxNEigbC=>		NXXYTm86cW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKG2rUl7BMVEzPCCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhPSEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzN{KyPUc,OjV6MUeyNlk9N2F-
A498	NEnVSZZHfW6ldHnvckBCe3OjeR?=	MlqzNVAhyrWP	NY\kXZlTPzJiaB?=		Mn:1bY5lfWOnczD0bIUhSUSDTWTTNVgh\2WwZTDlfJBz\XO\|aX;u	MkL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkmwPFYoRjJ3NU[5NFg3RC:jPh?=
CaKI-2	MXzGeY5kfGmxbjDBd5NigQ>?	MUWxNEDDvU1?	NX;LTIU6PzJiaB?=		MVjpcoR2[2W\|IITo[UBCTEGPVGOxPEBo\W6nIHX4dJJme3Orb36=	NXHmdWU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlkxQDZpPkK1OVY6ODh4PD;hQi=>
Ketr-3	M{fEeGZ2dmO2aX;uJGF{e2G7	MmXWNVAhyrWP	NX[yZZMxPzJiaB?=		NV[wVFY1cW6mdXPld{B1cGViQVTBUXRUOThiZ3Xu[UBmgHC{ZYPzbY9v	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4OUC4Okc,OjV3NkmwPFY9N2F-
A253	NGfqXJhHfW6ldHnvckBCe3OjeR?=	MYKxNEDDvU1?	MlT2NE01KGR?		MUDpcoNz\WG\|ZYOgeIhmKG2UTlGg[ZhxemW\|c3nvckBt\X[nbDDv[kB1cGViTUPSxsBi\nSncjCyOEBp	M3\ySFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEi1OVM3Lz5{NUS4OVU{PjxxYU6=
A253	MVjGeY5kfGmxbjDBd5NigQ>?	MVixNEDDvU1?	M2jv[VczKGh?		MnGxbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIITo[UBOO1JiaX6gZo91cCCvZX3idoFv\SCjbnSgZ5l1d3OxbHnjJJBz\XCjcnH0bY9vew>?	NWP4dJdCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PFU2OzZpPkK1OFg2PTN4PD;hQi=>
A253	M{fyNWZ2dmO2aX;uJGF{e2G7	NIHKNGQyOCEEtV2=	M2nCfVAuPCCm		MlH1doVlfWOnczD0bIUhPS2vZYTofYxkgXSxc3nu[UBkd262ZX70	M17XOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEi1OVM3Lz5{NUS4OVU{PjxxYU6=
PC3	MnfkSpVv[3Srb36gRZN{[Xl?	MYSwMlIh\|ryPwrC=	M2XxUVQh\A>?		NIDlUZRqdmO{ZXHz[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDJS2ZDWDduIGPGVnAyKGGwZDDTUGM3STF3IHPvcYJqdmWmIIfpeIghT1ONMUK2	NUewTGt7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{PDBpPkK1OFc4OzRyPD;hQi=>
MCF7	NX3IXpJ3TnWwY4Tpc44hSXO\|YYm=	Mn7HNE4{KM7:TdMg	MkHqOEBl		M2\FdIlv[3KnYYPld{B1cGViZ3Xu[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyxiU1\SVFEh[W6mIGPMR\|ZCOTViY3;tZolv\WRid3n0bEBIW0tzMk[=	M1nIXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N\|QxLz5{NUS3O\|M1ODxxYU6=
PC3	MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfNdmUxNjJizszNxsA>	M3rTWFQh\A>?		MXvk[YNz\WG\|ZYOgeIhmKGOnbHyg[5Jwf3SqIITvJFIxNjNnIHPvcYJqdmWmIIfpeIghT1ONMUK2	NFrqenI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|M1OCd-MkW0O\|c{PDB:L3G+
MCF7	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPHNE4{KM7:TdMg	MVK0JIQ>		MWTk[YNz\WG\|ZYOgeIhmKGOnbHyg[5Jwf3SqIEK0MlgmKGOxbXLpcoVlKHerdHigS3NMOTJ4	NULCe4ppRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{PDBpPkK1OFc4OzRyPD;hQi=>
BGC-823	Ml;ESpVv[3Srb36gRZN{[Xl?	Mkm4OeKh\|ryP	MkjxO\|IhcA>?		NWDqb3NE\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>?	NULNWotFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|U4OzNpPkK1OFc2PzN\|PD;hQi=>
MKN28	M2fyUGZ2dmO2aX;uJGF{e2G7	M3O5cFXDqM7:TR?=	NVH6[mVLPzJiaB?=		MkfU[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=>	NUXUeHVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|U4OzNpPkK1OFc2PzN\|PD;hQi=>
SGC-7901	M4TkN2Z2dmO2aX;uJGF{e2G7	MVW1xsDPxE1?	NGfKeGU4OiCq		MYfk[YNz\WG\|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5	NEiweI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3OVc{Oyd-MkW0O\|U4OzN:L3G+
MKN45	MYnGeY5kfGmxbjDBd5NigQ>?	MoHuOeKh\|ryP	MkDDO\|IhcA>?		M{[xb4Rm[3KnYYPld{B1cGViUGLMMVMheHKxdHXpckBt\X[nbDDzbYdvcW[lYX70cJk>	NGrIfXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3OVc{Oyd-MkW0O\|U4OzN:L3G+
BGC-823	M4LXbGZ2dmO2aX;uJGF{e2G7	M{XpfVXDqM7:TR?=	MkT0O\|IhcA>?		M2\DOoRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIGDSUE0{KHOrZ37p[olk[W62bIm=	NEPzfnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3OVc{Oyd-MkW0O\|U4OzN:L3G+
MKN28	MnHJSpVv[3Srb36gRZN{[Xl?	MoG5OeKh\|ryP	M{fDR\|czKGh?		M2TEZ4Rm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIGDSUE0{KHOrZ37p[olk[W62bIm=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5NUezN{c,OjV2N{W3N\|M9N2F-
SGC-7901	M4fGXWZ2dmO2aX;uJGF{e2G7	NX\RbW1JPcLizszN	NIXQfVc4OiCq		NGezR2dl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDQVmwuOyC\|aXfubYZq[2GwdHz5	M4S0e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe1O\|M{Lz5{NUS3OVc{OzxxYU6=
MKN45	M2THeGZ2dmO2aX;uJGF{e2G7	NVnXR2xkPcLizszN	NYLHS49pPzJiaB?=		MWLk[YNz\WG\|ZYOgeIhmKG2UTlGg[ZhxemW\|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7	MkP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{W3N\|MoRjJ3NEe1O\|M{RC:jPh?=
HREC	MnvJSpVv[3Srb36gRZN{[Xl?	MV61M\|ExyqEQvF2=	MnHWOFghcA>?		MWPpcoR2[2W\|IGDFSGYhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NV\aXYVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOVI4PDdpPkK1N\|UzPzR5PD;hQi=>
HRPE	MnW4SpVv[3Srb36gRZN{[Xl?	M3SxT\|UwOTEEoN88US=>	M13CUlQ5KGh?		M3zN[4lv\HWlZYOgVGVFTiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MkfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|NUK3OFcoRjJ3M{WyO\|Q4RC:jPh?=
HREC	MnzWSpVv[3Srb36gRZN{[Xl?	MmrrOU8yOMLizszN	NXTmUmd{PDhiaB?=		MkG4[I94di2{ZXf1cIF1\XNib3[gWmVITixiSVPBUU0yKCiwb4SgdJJwfGWrbjDs[ZZmdCCrbjDIVnBGKGOnbHzzLUwhUUxvMd8yJIRwe2VvZHXw[Y5l\W62bIm=	NV7qZmJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOVI4PDdpPkK1N\|UzPzR5PD;hQi=>
HRPE	M1vw[2Z2dmO2aX;uJGF{e2G7	NGDTW2Y2NzFywrFOwG0>	MVG0PEBp		MkLk[I94di2{ZXf1cIF1\XNib3[gWmVITixiSVytNe6zNCCjbnSgUW1ROiCmb4PlMYRmeGWwZHXueIx6	NFzhOIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO1Nlc1Pyd-MkWzOVI4PDd:L3G+
MSCs	NUPJO3BlTnWwY4Tpc44hSXO\|YYm=	NVL2T3BCOTBizszN	NWL6SZpyOjRiaB?=		M1H0NJBzd22xdHXzJJRp\SClb33tbZRu\W62IH;mJG1US3NidH:gcZlw[2G{ZHnhcEBlcW[oZYLlcpRq[XSrb36=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN3MUO5OUc,OjV\|NUGzPVU9N2F-
HL-60	M3zifGZ2dmO2aX;uJGF{e2G7	NFvR[pc2KM7:TR?=	NHG2T3Y4OiCq	NWnB[3hKTE2VTx?=	NIDa[Hl{cWewaX\pZ4FvfGy7IIXwdoVofWyjdHXzJHpPTjN6MjDlfJBz\XO\|aX;u	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNzOUC0PUc,OjV\|MUmwOFk9N2F-
MV4-11	Ml[1SpVv[3Srb36gRZN{[Xl?	MYK1JO69VQ>?	NHPESJI4OiCq	M3rGPWROW09?	MnX1d4lodmmoaXPhcpRtgSC3cILl[5Vt[XSnczDaUmY{QDJiZYjwdoV{e2mxbh?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNzOUC0PUc,OjV\|MUmwOFk9N2F-
A2780	NXGwe3RRTnWwY4Tpc44hSXO\|YYm=	M3jEcVUhyrWPwrC=	NEGySZc4KGR?		MlTxbY5kemWjc3XzJGRPSSCvZYTofYxifGmxbjDs[ZZmdA>?	M4LLPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm5Olk1Lz5{NUK5PVY6PDxxYU6=
CP70	MWTGeY5kfGmxbjDBd5NigQ>?	NFnhT2w2KML3TdMg	NG\GenI4KGR?		NXrQWmNNcW6lcnXhd4V{KESQQTDt[ZRpgWyjdHnvckBt\X[nbB?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7OU[5OEc,OjV{OUm2PVQ9N2F-
A2780	NIfLemZHfW6ldHnvckBCe3OjeR?=	NF\sPJQ2KML3TdMg	MmXsO{Bl		MYT3[YFs\W6\|IITo[UBt\X[nbDDv[kBu\XSqeXzheIlwdg>?	M{nuelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm5Olk1Lz5{NUK5PVY6PDxxYU6=
CP70	M4nTT2Z2dmO2aX;uJGF{e2G7	MmPnOUDDvU4EoB?=	NVLrTWl[PyCm		NUnZN2pif2Wja3Xud{B1cGVibHX2[Ywhd2ZibXX0bJlt[XSrb36=	NUnle3NsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVk3QTRpPkK1Nlk6Pjl2PD;hQi=>
OCM3	M2rxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml75NE42NzFxMjFOwG0>	NWfuO\|QyPyCm	M4LFbmROW09?	M4fkO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NIKxSGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
92.1	M4O4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXQeWIxNjVxMT:yJO69VQ>?	MYq3JIQ>	M1vpPWROW09?	M3K3VolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	M4fMclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
OCM1	M1jEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\RW4UxNjVxMT:yJO69VQ>?	NWTJPXNCPyCm	NGrubZRFVVOR	NFj3b49qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NXn1[nltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
OMM1	NXzIWWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlK4NE42NzFxMjFOwG0>	MVS3JIQ>	M3LDbGROW09?	NELuPXVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NVnMdGVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
Mel 285	M13MNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHteVYxNjVxMT:yJO69VQ>?	NEXHcmk4KGR?	M1LGbGROW09?	MX;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MlfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
Mel 290	NWDFZoh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jGPVAvPS9zL{Kg{txO	MnWxO{Bl	MXzEUXNQ	M3;nPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	M3nTXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
OCM3	M3TsWWZ2dmO2aX;uJGF{e2G7	M4LVelAvPS9zIN88US=>	NF;lVWU1QCCq	Ml7WSG1UVw>?	NYC4WohQ\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?=	MmXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
92.1	MnnQSpVv[3Srb36gRZN{[Xl?	Mo\vNE42NzFizszN	NUi1VotyPDhiaB?=	MmHSSG1UVw>?	M2TyToRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl?	NIfzPVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
OCM1	M2XkUGZ2dmO2aX;uJGF{e2G7	M3vBXVAvPS9zIN88US=>	MnfCOFghcA>?	M3;hU2ROW09?	MWHk[YNz\WG\|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6	M3HYV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
OMM1	NFvKTm5HfW6ldHnvckBCe3OjeR?=	NHHHN2wxNjVxMTFOwG0>	M{TvdlQ5KGh?	NX3sRXFvTE2VTx?=	M3zpXYRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl?	NFrhXYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
Mel 285	Ml\ySpVv[3Srb36gRZN{[Xl?	NFHSPFUxNjVxMTFOwG0>	NV73[GRrPDhiaB?=	MorBSG1UVw>?	MXrk[YNz\WG\|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6	NHrxZ5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
Mel 290	M1j2NGZ2dmO2aX;uJGF{e2G7	M3\iNlAvPS9zIN88US=>	M1PrW\|Q5KGh?	MlWwSG1UVw>?	MmPM[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>?	NGjpVmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
OCM3	NYPufINbTnWwY4Tpc44hSXO\|YYm=	NV\LOmF4OC53L{Gg{txO	MXm0PEBp	MUXEUXNQ	NHKydJNl\WO{ZXHz[ZMhcW64YYPpc44h\G:\|ZTDk[ZBmdmSnboTsfeKh	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2Nkm4NUc,OjVzNE[5PFE9N2F-
Mel 290	M{PuUmZ2dmO2aX;uJGF{e2G7	NYPzbmxGOC53L{Gg{txO	MYW0PEBp	MV3EUXNQ	M3rZV4Rm[3KnYYPld{Bqdn[jc3nvckBld3OnIHTldIVv\GWwdHz5xsA>	M{jEdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
OMM1	NW\UOpdmTnWwY4Tpc44hSXO\|YYm=	MXmwMlUwOSEQvF2=	MkLGOFghcA>?	MkDCSG1UVw>?	NIPYepRl\WO{ZXHz[ZMhcW64YYPpc44h\G:\|ZTDk[ZBmdmSnboTsfeKh	M2DN[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
OCM1	M4\DZmNmdGxiVnnhZoltcXS7IFHzd4F6	MXywMlUwOSEQvF2=	MVS1JIQ>	Mmi5SG1UVw>?	MnHU[IVkemWjc3XzJJJi\GmjdHnvck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHnubIljcXSrb36=	NITPWIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
92.1	M1LhWWNmdGxiVnnhZoltcXS7IFHzd4F6	NXjUfVR2OC53L{Gg{txO	MWG1JIQ>	NWizcGIyTE2VTx?=	MXPk[YNz\WG\|ZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliaX7obYJqfGmxbh?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2Nkm4NUc,OjVzNE[5PFE9N2F-
OCM1	MUPGeY5kfGmxbjDBd5NigQ>?	MkLtNE42NzFizszN	NWrpd\|ZZPDhiaB?=	MmLkSG1UVw>?	MlvaZ4F2e2W\|IHfsc4JidCCGTlGgbJlxd22ndHj5cIF1cW:wIHH0JGwuOSC{ZYDlZZQhdG:laR?=	NYjhT\|BFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
OCM3	M3n5bmZ2dmO2aX;uJGF{e2G7	MYCwMlUwOSEQvF2=	NWnPbopVPDhiaB?=	NX\COpJmTE2VTx?=	NUi0RY1y[2G3c3XzJIdtd2KjbDDEUmEhcHmyb33leIh6dGG2aX;uJIF1KExvMTDy[ZBm[XRibH;jbS=>	NHLwNJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
92.1	NHz3fWJHfW6ldHnvckBCe3OjeR?=	NEjCSmUxNjVxMTFOwG0>	Ml2xOFghcA>?	NUGyWGNvTE2VTx?=	Mnr2Z4F2e2W\|IHfsc4JidCCGTlGgbJlxd22ndHj5cIF1cW:wIHH0JGwuOSC{ZYDlZZQhdG:laR?=	Ml7ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
IMR32	M3K5V2Z2dmO2aX;uJGF{e2G7	NYSzVVZ4OyEQvF2=	NGTzdWY4OiCq	NFvmZ2tFVVOR	MV\pcoR2[2W\|wrDwNVkuUU6NNHVCpIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm=	M4Xve\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC0PFUxLz5{NUGwOFg2ODxxYU6=
IMR5-75	M3;PTGZ2dmO2aX;uJGF{e2G7	M1G1bFMh\|ryP	NWLRTGp{PzJiaB?=	MWfEUXNQ	Ml;TbY5lfWOnc9MgdFE6NUmQS{TkxsBmgHC{ZYPzbY9vyqC\|aXfubYZq[2GwdHz5	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyNEi1NEc,OjVzMES4OVA9N2F-
Be(2)-C	MoTPSpVv[3Srb36gRZN{[Xl?	M2HFR\|Mh\|ryP	NV\rbW1NPzJiaB?=	NHLX[IhFVVOR	MX;pcoR2[2W\|wrDwNVkuUU6NNHVCpIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm=	NFLhdoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwOFg2OCd-MkWxNFQ5PTB:L3G+
Bxpc-3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLTOU8yOCEQvF2=	MX2yOE81QC95MjDo		M3S1PYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJI9nKEK6cHOtN{Bk\WyuczDpckB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{cx?=	NHjvcpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVc{OSd-MkWwOlE4OzF:L3G+
Bxpc-3	NHW2cXhCeG:ydH;zbZMhSXO\|YYm=	NVnEeFE2PS9zMDFOwG0>	MoDUNlQwPDhxN{KgbC=>		NFvl[YFqdmS3Y3XzJIFxd3C2b4Ppd{BqdiC2aX3lMUBidmRiY3;uZ4VzdnS{YYTpc44hdWGwbnXydy=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUezNUc,OjVyNkG3N\|E9N2F-
Bxpc-3	NET1PFJHfW6ldHnvckBCe3OjeR?=	NFjmSZU2NzFyIN88US=>	NEfVUoUzPC92OD:3NkBp		M2LP[oRm[3KnYYPld{DPui2lYYTlcolvKGW6cILld5Nqd25iYX\0[ZIhOjRiaB?=	NYrGOJU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlE4OzFpPkK1NFYyPzNzPD;hQi=>
Bxpc-3	Mkn4SpVv[3Srb36gRZN{[Xl?	Mo\uOU8yOCEQvF2=	NUjXfo02OjRxNEivO\|IhcA>?		NEflXY1l\WO{ZXHz[ZMh[3mlbHnuSFEh\XiycnXzd4lwdiCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhOTBizszN	MnHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkG3N\|EoRjJ3ME[xO\|MyRC:jPh?=
Bxpc-3	M2q5Z2Z2dmO2aX;uJGF{e2G7	MUO1M\|ExKM7:TR?=	NUfHOZhQOjRxNEivO\|IhcA>?		MW\kc5dvNXKnZ4XsZZRmWyClLX35Z{BuWk6DIHX4dJJme3Orb36gbY4hfGmvZT2gZY5lKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6ncoO=	Mk\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkG3N\|EoRjJ3ME[xO\|MyRC:jPh?=
HL-60	M3L3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PIUVEvOCEQvF2=	MoDlOFghcA>?		M4X3UJNq\26rZnnjZY51dHliaX7obYJqfHNiSFytOlAh[2WubDDndo94fGkEoB?=	NXG5cZVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVEyOTlpPkK1NFUyOTF7PD;hQi=>
HL-60	NFHwW5hHfW6ldHnvckBCe3OjeR?=	MUmxMlAh\|ryP	NYS0dpFqPDhiaB?=		M1no[4lv[3KnYYPld{BxOjGZQV[xM2NKWDIEoHHu[EBk[XOyYYPlMVMh\XiycnXzd4lwdsLi	M2fqPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWxNVE6Lz5{NUC1NVEyQTxxYU6=
HL-60	NV3le5NtTnWwY4Tpc44hSXO\|YYm=	NEfTSo0yNjBizszN	NXzuc3h7PDhiaB?=		MlPQ[IVkemWjc3XzJGJkdC26TDDlfJBz\XO\|aX;uxsB{cWewaX\pZ4FvfGy7	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3MUGxPUc,OjVyNUGxNVk9N2F-
HuTu-80	NF6wdFVHfW6ldHnvckBCe3OjeR?=	MlnZNU82NzFyIN88US=>	NH7XXHI1QC95MjDo		M4rqdYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBpfW2jbjDOVGMyVDFibWLORUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NHPHe2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwOFA3Oid-MkS5NFQxPjJ:L3G+
Caco2	NFjDNYdHfW6ldHnvckBCe3OjeR?=	M3rPT\|ExKM7:TR?=	NH7Fbm81QCCq		MULpcoNz\WG\|ZYOgUnBEOUxzIHX4dJJme3Orb36=	NXXyXWtORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFQxPjJpPkK0PVA1ODZ{PD;hQi=>
HepG2	NYXMfplZTnWwY4Tpc44hSXO\|YYm=	M1jNb\|AuOjVizszN	M1;ZZlI1KGh?		MmPY[IVkemWjc3XzJJN2[nSrbHnzbY4wc2W6aX6geJlx\SB7IDjQR3NMQSlicILveIVqdiCuZY\lcJMh\G:\|ZTDk[ZBmdmSnboTsfS=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh3NU[0Okc,OjR6NUW2OFY9N2F-
HepG2	M1vYVmZ2dmO2aX;uJGF{e2G7	NILHc3YxNTJ3IN88US=>	MUmyOEBp		MWLpcoNz\WG\|ZYOgcI94KGSnboPpeJkhdGmyb4Dyc5RmcW5icnXj[ZB1d3JiKFzEUHIqKGenbnWg[ZhxemW\|c3nvcuKh	NHf3eGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1OVY1Pid-MkS4OVU3PDZ:L3G+
HepG2	MUXGeY5kfGmxbjDBd5NigQ>?	NFXGPVYyOCEQvH5CpC=>	M3G3ZVAuOjRiaB?=		MVzk[YNz\WG\|ZYRCpHBEW0t7wrDhcoTDqEiPR1PSxsBmgHC{ZYPzbY9vKGGwZDDpcoNz\WG\|ZYOgUGRNWiCneIDy[ZN{cW:wIHHmeIVzKDZiaB?=	NEXYXmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1OVY1Pid-MkS4OVU3PDZ:L3G+
HepG2	MmW4SpVv[3Srb36gRZN{[Xl?	NH\Bc5EyOCEQvH2=	MXWyOEBp		MVPwdo9ud3SnczDjfZRwe2:uaXOgcoV2fHKjbDDsbZBq\CCjY3P1cZVt[XSrb36gbY5l\XCnbnTlcpRtgSCxZjDlfI9o\W6xdYOgcIlxd3C{b4TlbY5{	NECwPJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1OVY1Pid-MkS4OVU3PDZ:L3G+
HepG2	MmnQSpVv[3Srb36gRZN{[Xl?	Mn7RNVAh\|ryv	NELweGQzPCCq		MkLudJJmfmWwdIOgV3JGSlBicILvZ4V{e2mwZx?=	MoXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUW2OFYoRjJ2OEW1OlQ3RC:jPh?=
HC45	MnrzSpVv[3Srb36gRZN{[Xl?	MW[1xtVOyqB?	MYi0JIQ>		M1n2dpJm\HWlZYOgeIhmKG2ndHj5cIF1cW:wIHzleoVteyCxZjDXTWYyNCCSMU[sJGNZS0xzNDygUmtZOuLCk{OsJGNFUDFuIFzBUWEyNCCjbnSgR3RPVkJz	MlXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NkK4NFkoRjJ2N{[yPFA6RC:jPh?=
CNDT2	MUTGeY5kfGmxbjDBd5NigQ>?	M1nQVFXDvU4EoB?=	NXqwOYFjPCCm		NWnS[FRlemWmdXPld{B1cGVibXX0bJlt[XSrb36gcIV3\Wy\|IH;mJHdKTjFuIGCxOkwhS1iFTEG0MEBPU1h{4pETN{whS0SKMTygUGFOSTFuIHHu[EBEXE6QQkG=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4MkiwPUc,OjR5NkK4NFk9N2F-
CNDT2	MoC2SpVv[3Srb36gRZN{[Xl?	M3HjfVXDvU4EoB?=	NVPkRmNTPCCm		MkXzbY5kemWjc3XzJIdmdmViZYjwdoV{e2mxbjDv[uKhX0mIMTygVFE3NCCFRFixMOKhVEGPQUGsxsBidmUEoFPUUm5DOQ>?	NEPL[YY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2NlgxQSd-MkS3OlI5ODl:L3G+
T-cells	NXT6XGh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlf3OU8zOCEQvF2=	MU[wMVQ5KGh?		M1XIUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MmfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NUeyPFMoRjJ2N{W3Nlg{RC:jPh?=
CD3+ T-cells	NV;iWlNTTnWwY4Tpc44hSXO\|YYm=	NFWyNGw2NzJyIN88US=>	NE\HNIk1QCCq		NIe2S2l2eHKnZ4XsZZRmeyCyMUWg[ZhxemW\|c3nvci=>	NF;YXZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O\|I5Oyd-MkS3OVczQDN:L3G+
CD4+ T-cells	NFXsSItHfW6ldHnvckBCe3OjeR?=	M1nXSFUwOjBizszN	MmXuOFghcA>?		M2fENJVxemWpdXzheIV{KHBzNTDlfJBz\XO\|aX;u	Mn7rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NUeyPFMoRjJ2N{W3Nlg{RC:jPh?=
CD8+ T-cells	MlLoSpVv[3Srb36gRZN{[Xl?	NH\HOIY2NzJyIN88US=>	Mnn6OFghcA>?		MXX1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?=	NHnwUJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O\|I5Oyd-MkS3OVczQDN:L3G+
CD3+ T-cells	Mn35SpVv[3Srb36gRZN{[Xl?	M2XVTlUwOjBizszN	NELq[\|k1QCCq		NFz4eW12eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCIT2jQNy=>	M3TEUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W3Nlg{Lz5{NEe1O\|I5OzxxYU6=
CD4+ T-cells	MnnXSpVv[3Srb36gRZN{[Xl?	NGL2c5g2NzJyIN88US=>	NGX1dXI1QCCq		NXXDOopbfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiRl;YVFM>	NH;qe\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O\|I5Oyd-MkS3OVczQDN:L3G+
CD4+ T-cells	MoHwSpVv[3Srb36gRZN{[Xl?	M4L5TFUwOjBizszN	MoCwOFghcA>?		Mn;CdoVlfWOnczDURmVVOcLibWLORUBmgHC{ZYPzbY9v	NFjvPIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O\|I5Oyd-MkS3OVczQDN:L3G+
CD4+ T-cells	NYX2bnBKTnWwY4Tpc44hSXO\|YYm=	MVi1M\|IxKM7:TR?=	NGnYcYU1QCCq		NXuxW2hNfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2cEoGLPVu6{fMLi	MnHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NUeyPFMoRjJ2N{W3Nlg{RC:jPh?=
CD4+ T-cells	MkfXSpVv[3Srb36gRZN{[Xl?	NIrUbJg2NzJyIN88US=>	M1fBfFQ5KGh?		NVfOcJdCcW6qaXLpeJMhdWWvb4L5JHQu[2WubIO=	M1\3WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W3Nlg{Lz5{NEe1O\|I5OzxxYU6=
CD8+ T-cells	NF:3RWxHfW6ldHnvckBCe3OjeR?=	NVvDRXRNPS9{MDFOwG0>	NVzxbldZPDhiaB?=		MXXpcohq[mm2czDt[Y1wenliVD3j[Yxtew>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd3N{K4N{c,OjR5NUeyPFM9N2F-
CD3+ T-cells	MUHGeY5kfGmxbjDBd5NigQ>?	M2nFd\|Uh\|ryP	M1XCVVQ5KGh?		M1m4SJJm\HWlZYOgcI9v\y22ZYLtJI1mdW:{eTDj[YxtKHCqZX7veJlx\Q>?	M2ewZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W3Nlg{Lz5{NEe1O\|I5OzxxYU6=
U937	NETLV2RCeG:ydH;zbZMhSXO\|YYm=	NXPhWG1lOTBizszN	NVXpcFkyPzJiaB?=		MWHpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	M2XFT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiwPFY2Lz5{NE[4NFg3PTxxYU6=
HL-60	M1LHcWFxd3C2b4Ppd{BCe3OjeR?=	MoDTNVAh\|ryP	NF\kfYs4OiCq		NXfWfZdPcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6MEi2OUc,OjR4OEC4OlU9N2F-
MCF7	MoLqSpVv[3Srb36gRZN{[Xl?	MlLZOUDPxE1?	NIT2NFU1QCCqwrC=		NXXXcXho\Gm\|cHzhfZMhe2WuZXP0bZZmKHSxeHnjbZR6KHSxd3Hy[EB{fXOyZX7k[YQhVUOILUegZ4VtdHN?	M4rTZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOzN\|UxLz5{NE[zN\|M2ODxxYU6=
MCF7	NEXPfWhHfW6ldHnvckBCe3OjeR?=	MWOxNEDPxE1?	NH;mdHQzPCCqwrC=		NIq5XVRqdmS3Y3XzJJRp\SClbHXheoFo\SCxZjDjZZNx[XOnIEegZY5lKFCDUmFCpC=>	MnfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{OzOVAoRjJ2NkOzN\|UxRC:jPh?=
MCF7	MVPGeY5kfGmxbjDBd5NigQ>?	NHfoSHEx6oDVMD61JO69VcLi	NF;YWHM4KGR?		MlPybY5pcWKrdIOgeIhmKGe{b4f0bEBOS0ZvNzD0eY1wenOyaHXy[ZMhcW5ic4XzdIVve2mxbjDjeYx1fXKnc9Mg	NIi0V2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zN\|M2OCd-MkS2N\|M{PTB:L3G+
MCF7	NGi0e4pHfW6ldHnvckBCe3OjeR?=	NFjh[FAxNjVizszNxsA>	NV7JcZBOOTRiZB?=		MojSdoVlfWOnczD0bIUhe2m8ZTDv[kBOS0ZvNzDjc4xwdmmnczDlcYJm\GSnZDDpckB{d2[2IHHnZZI>	MlfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{OzOVAoRjJ2NkOzN\|UxRC:jPh?=
MCF7	M1:3SGZ2dmO2aX;uJGF{e2G7	NFfZZ3gxNjB34pETNlAh\|ryP	M37DN\|Eh\A>?		NXPCfYJGemWmdXPld{B1cGViY3zvcoFtKHO3co\peoFtKG:oIF3DSk04KGOnbHzzJIlvKG2xbn;sZZlmeiCldXz0eZJmew>?	MoXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{OzOVAoRjJ2NkOzN\|UxRC:jPh?=
T47D	NHG2UIlHfW6ldHnvckBCe3OjeR?=	MlnxNE42KM7:TR?=	NXPMO5BlPCCm		MVnpcohq[mm2czD0eY1wenOyaHXy[UBnd3KvYYTpc44>	M{\xS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOzN\|UxLz5{NE[zN\|M2ODxxYU6=
MCF7	Mn3ESpVv[3Srb36gRZN{[Xl?	MVqwMlXjiJNzMDFOwG0>	M4fxTlQ5KGkEoB?=		NIDhWmRqdmirYnn0d{B1cGViZ3HwJINtd3O3cnWgbY4hfGinIIfveY5lKGinYXzpcoch[XO\|YYm=	NGXneVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zN\|M2OCd-MkS2N\|M{PTB:L3G+
MCF7	NXzkdVVGTnWwY4Tpc44hSXO\|YYm=	NGLa[I8xNzFyIN88US=>	NH\rRZYzPCCq		NHTCO2dqdmirYnn0d{B1cGViYXP0bZZqfHlib3[gUW1RQQ>?	NGXmSlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zN\|M2OCd-MkS2N\|M{PTB:L3G+
MDA-MB-231	NVfqc2V[TnWwY4Tpc44hSXO\|YYm=	NXzYXph2OC534pETNVAh\|ryP	M3jvblM3KGh?		MmTHbY5pcWKrdIOgeIhmKG2rZ4LheIlwdg>?	M3PvVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOzN\|UxLz5{NE[zN\|M2ODxxYU6=
SKM1-S	NW\WNmtlSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mn\jOFghcHK\|		M4H3PGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1vNNU1UKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDYWHQh[XO\|YYmsJGlEPTBiPTCwMlUh\|ryPLh?=	NILUU289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC5OFk{QCd-MkiwPVQ6Ozh:L3G+
SKM1-S	Mn:1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHfkdHM1QCCqcoO=		MlXJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVS12xMXMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IFTBVGkue3SjaX7pcocu[mG\|ZXSg[oxwfyCleYTvcYV1emmlIH3leIhw\CxiRVO1NEA:KDBwNUGg{txONg>?	M2e2flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEm0PVM5Lz5{OEC5OFk{QDxxYU6=
A427	M1vyeWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWO5OkBpenN?		M4jSW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUSyO{Bk\WyuczDh[pRmeiB7NjDodpMh[nliY4L5d5RidCC4aX;s[ZQh[XO\|YYmsJGlEPTBiPTCwMlY{KM7:TT6=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR\|NEG2N{c,OTh2M{SxOlM9N2F-
KYSE70	NUTBVIU5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWe5OkBpenN?		Mn\VRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNWWPFO\|Ah[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IHPyfZN1[WxidnnvcIV1KGG\|c3H5MEBKSzVyIE2gNU42QSEQvF2u	NEnRbnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESzOFE3Oyd-MUi0N\|QyPjN:L3G+
5637	M{LLT2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2LrWVk3KGi{cx?=		NEnSd4ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEW2N\|ch[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IHPyfZN1[WxidnnvcIV1KGG\|c3H5MEBKSzVyIE2gNU44OyEQvF2u	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR\|NEG2N{c,OTh2M{SxOlM9N2F-
HT-29	MkXoRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYH4WJBZQTZiaILz		M3e3dWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEOuPEDPxE1w	NWHFOG5QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3PFQ1QSd-Mke3PFQ1QTxxYU6=
P388	MX;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmLFOFghcHK\|		NUnpWYg{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDQN\|g5KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC1JO69VS5?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd6NES5K\|4zPzd6NES5QE9iRg>?
MCF7	NUfVUoh1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M{iwNVk3KGi{cx?=		NH7sTGZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IHPyfZN1[WxidnnvcIV1KGG\|c3H5MEBKSzVyIE2gOk44QCEQvF2u	NVTiTnV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0N\|QyPjNpPkG4OFM1OTZ\|PD;hQi=>
U373-MAGI	NX3xXJZ3SW62aY\pdoFtKGG\|c3H5	M{O0PFI2KHSxIESwNEB2VQ>?	NY\pfYJyOiC2bzC3NkBpenN?		MXvBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDWV3YuTyCyc3X1[I91gXCnZDDITXYuOSCQTEStN{Bqdm[nY4Tl[EBqdiCqdX3hckBWOzd\|LV3BS2kh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHfh[{Bt\X[nbDDheEAzPSC2bzC0NFAhfU1iYX\0[ZIhOiC2bzC3NkBpenNiYomgdXBEWiCvZYToc4Q>	M2DvOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO\|I3ODxxYU6=
U373-MAGI	MkjWRY51cX[rcnHsJIF{e2G7	NEnv[\|YzPSC2bzC0NFAhfU1?	NIDSTGQzKHSxIEeyJIhzew>?		NFvkNWtCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBXW1ZvRzDwd4V2\G:2eYDl[EBJUVZvMTDOUFQuOyCrbn\lZ5Rm\CCrbjDoeY1idiCXM{ezMW1CT0liY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHU2NWejZzDs[ZZmdCCjdDCyOUB1dyB2MECgeW0h[W[2ZYKgNkB1dyB5MjDodpMh[nlicWDDVkBu\XSqb3S=	M2jlS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO\|I3ODxxYU6=
L1210	MoTzR5l1d3SxeHnjbZR6KGG\|c3H5				MoL3R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUFEzOTBiY3XscJMh[XO\|ZYPz[YQh[XNiY3Xzd4F1cW:wIH;mJIdzd3e2aB?=	NFfMZZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi94OUCyOkc,PjlyMk[8M4E,
TC32	MXrxTHRUKGG\|c3H5				NIHHcodyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	MkPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	MlrOdWhVWyCjc4PhfS=>				M3jhZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	MlLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	MUDxTHRUKGG\|c3H5				M3TFTJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	MlTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NGf4eFhyUFSVIHHzd4F6				NGr3VZpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	M1:2XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	Mn\FdWhVWyCjc4PhfS=>				NXvDWINCeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	NWfT[nZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	NFnYdnRyUFSVIHHzd4F6				MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MnzCdWhVWyCjc4PhfS=>				M1rR[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	MnryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	M13HZpFJXFNiYYPzZZk>				NWDQUmt6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	M1TGR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SKM1-S	MoHLRZBweHSxc3nzJIF{e2G7	NEDVPWoyKHWP			NXrrdZZ{UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDTT20yNVNiY3XscJMh[XO\|ZYPz[YQh[XNiY3HzdIF{\SB\|IHPs[YF3[WenIHH0JFEhfU1iYomgW4V{fGW{bjDicI91KG2ndHjv[C=>	NFzyOpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC5OFk{QCd-MkiwPVQ6Ozh:L3G+
MCF7	MV7GeY5kfGmxbjDhd5NigQ>?	NXv2fG95OTVidV2=	MXm3NkBpenN?		NXrF[2pWUW6qaXLpeIlwdiCxZjDVTHJHOSCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKG2ndHj5cIF1cW:wIHH0JHJCWiCkZYThJIV5d25iYYSgNVUhfU1iYX\0[ZIhPzJiaILzJIJ6KG2ndHj5cIF1cW:wIIPw[YNq\mmlLWDDVkBu\XSqb3S=	M3fQeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MES5OVc4Lz5{N{C0PVU4PzxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 ; PubMed: 28210112 Lung Cancer (Auckl) AZA and DAC cause DNMT1 depletion in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–5 µM) for 20 hours and DNMT1 protein was detected by Western blotting of cell extracts. Alpha-tubulin was used as a loading control. c-PARP / p-H2AX / H2AX; PubMed: 28210112 Lung Cancer (Auckl) AZA, but not DAC, induces markers of DNA damage and apoptosis in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–10 µM) for 48 hours and Western blotting of cell extracts was used to detect DNMT1, cleaved-PARP, phospho-histone-H2AX(䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘	28210112
Immunofluorescence	HMGB1 ; PubMed: 29097772 Sci Rep U2OS cells stably expressing a GFP-HMGB1 fusion were maintained in control conditions (Ctrl), suberoylanilide hydroxamic acid (SAHA), azacitidine (AZA) for 24 h or 48 h, followed by assessment of cytoplasmic GFP-HMGB1 fluorescence intensity (A,B) or endog䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕𢡄⟼෕䀷痗⟼෕౴⟼෕㵶痗⟼෕뺖᎒泌Itemｾ᎒	29097772
Growth inhibition assay	Cell viability ; PubMed: 28210112 Lung Cancer (Auckl) AZA and DAC differentially affect cell viability in a panel of NSCLC cell lines. Viability of A549, H460, and H1299 cells was assessed after 72 hours of treatment with AZA or DAC (0–25 µM). Error bars represent the standard error of mean of 3 independent 䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖	28210112

In vivo

Azacitidine inhibits polynucleotide synthesis in leukemic BDF₁ mice. ^[3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. ^[4]

Protocol

Cell Research:^[3]	- Collapse Cell lines: Leukemia L1210 cell Concentrations: 0.15 μg/mL Incubation Time: 3 days Method: 5 mL of L1210 cells (5 × 10³ cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter. (Only for Reference)
Animal Research:^[4]	- Collapse Animal Models: BDF1 mice bearing lymphoid leukemia L1210 Dosages: 3 mg/kg Administration: Daily i.p. injection (Only for Reference)

References

[4] Heby O, et al. Cancer Res. 1973, 33(1), 159-165.

- Collapse

Solubility (25°C)

In vitro	DMSO	48 mg/mL warmed (196.56 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Azacitidine (5-Azacytidine) SDF

Molecular Weight	244.2
Formula	C₈H₁₂N₄O₅
CAS No.	320-67-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	5-AzaC,Ladakamycin, AZA,5-Aza
Smiles	C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04638309	Not yet recruiting	Drug: APR-548 + Azacitidine	MDS\|Myelodysplastic Syndromes	Aprea Therapeutics	March 2021	Phase 1
NCT04689815	Recruiting	Drug: Oral Arsenic Trioxide Formulation	NPMc+ AML	The University of Hong Kong	January 1 2021	Phase 2
NCT04629443	Not yet recruiting	Drug: S 64315 (also referred as MIK665) and azacitidine	Acute Myeloid Leukaemia	Institut de Recherches Internationales Servier\|ADIR a Servier Group company\|Servier	November 16 2020	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?
Answer:
S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

Choose Your Country or Region

By Signaling Pathways

By product type

Azacitidine (5-Azacytidine)